1. Field of the Invention
The present invention relates generally to medical methods and systems. More particularly, the invention is directed to methods and systems for treating and determining physiologic characteristics of body lumens such as the esophagus.
The human body has a number of internal body lumens or cavities located within, many of which have an inner lining or layer. These inner linings can be susceptible to disease. In some cases, surgical intervention can be required to remove the inner lining in order to prevent the spread of disease to otherwise healthy tissue located nearby.
Those with persistent problems or inappropriate relaxation of the lower esophageal sphincter can develop a condition known as gastroesophageal reflux disease, manifested by classic symptoms of heartburn and regurgitation of gastric and intestinal content. The causative agent for such problems may vary. Patients with severe forms of gastroesophageal reflux disease, no matter what the cause, can sometimes develop secondary damage of the esophagus due to the interaction of gastric or intestinal contents with esophageal cells not designed to experience such interaction.
The esophagus is composed of three primary tissue layers; a superficial mucosal layer lined by squamous epithelial cells, a middle submucosal layer and a deeper muscle layer. When gastroesophageal reflux occurs, the superficial squamous epithelial cells are exposed to gastric acid, along with intestinal bile acids and enzymes. This exposure may be tolerated, but in some cases can lead to damage and alteration of the squamous cells, causing them to change into taller, specialized columnar epithelial cells. This metaplastic change of the mucosal epithelium from squamous cells to columnar cells is called Barrett's esophagus, named after the British surgeon who originally described the condition.
Barrett's esophagus has important clinical consequences, since the Barrett's columnar cells can, in some patients, become dysplastic and then progress to a certain type of deadly cancer of the esophagus. The presence of Barrett's esophagus is the main risk factor for the development of adenocarcinoma of the esophagus.
Accordingly, attention has been focused on identifying and removing this abnormal Barrett's columnar epithelium in order to mitigate more severe implications for the patient. Devices and methods for treating abnormal body tissue by application of various forms of energy to such tissue have been described, such as radio frequency ablation. However, without precise control of the depth of penetration of the energy means, these methods and devices are deficient. Uncontrolled energy application can penetrate too deeply into the esophageal wall, beyond the mucosa and submucosal layers, into the muscularis externa, potentially causing esophageal perforation, stricture or bleeding. Accordingly, proper administration of the correct amount of treatment energy to the tissue can be facilitated by knowledge of the size of the esophagus and area to be treated.
Additionally, medical procedures for treating Barrett's esophagus typically involve deployment of an expandable catheter inside the esophagus. Expandable catheters are preferred because the profile of the catheter is ideally as small as possible to allow for ease of delivery, while treatment of the esophagus is most efficiently performed when the catheter is at or slightly larger than the diameter of the esophageal wall. Proper sizing and/or pressurization of the delivery device is therefore desirable to prevent over-distension of the organ, which could result in harm to the organ, or under-expansion of the catheter, which often results in incomplete treatment. Accordingly, accurate and simple measurement of the size of the lumen and control of the pressure of the catheter on the lumen surface promotes the proper engagement and delivery of energy to the luminal wall so that a uniform and controlled depth of treatment can be administered. In addition to calculating luminal dimensions, the compliance of the lumen can be determined by measuring the cross section of the lumen at two or more pressure values.
Therefore, it would be advantageous to have methods and systems for accurately determining in vivo the size and optionally the compliance of a body lumen such as the esophagus. In addition, it would be desirable to provide a method and system for treating the body lumen once having determined its size. At least some of these objectives will be met by the present invention.
2. Description of the Background Art
U.S. Pat. No. 5,275,169 describes apparatus and methods for determining physiologic characteristics of blood vessels. The device measures the diameter and wall compliance of the blood vessel, and does not administer treatment. Additionally, the method relies on using only an incompressible fluid to inflate a balloon inside a blood vessel. Other patents of interest include U.S. Pat. Nos. 6,010,511; 6,039,701; and 6,551,310.
The present invention comprises methods and systems for sizing a body lumen, such as the esophagus. Methods and systems are also provided for treating the body lumen once the proper measurements have been made.
Although the following description will focus on embodiments configured for treatment of the esophagus, other embodiments may be used to treat any other suitable lumen in the body. In particular, the methods and systems of the present invention may be used whenever accurate measurement of a body lumen or uniform delivery of energy is desired to treat a controlled depth of tissue in a lumen or cavity of the body, especially where such body structures may vary in size. Therefore, the following description is provided for exemplary purposes and should not be construed to limit the scope of the invention.
In one aspect of the invention, a method for treating a body lumen at a treatment location comprises measuring a luminal dimension at the treatment location of the lumen, selecting an electrode deployment device having an array of electrodes or other electrode structure with a pre-selected deployed size which corresponds to the measured dimension, positioning the electrode deployment device at the treatment location within the lumen, deploying the electrode array to the pre-selected deployed state to engage a wall of the lumen, and delivering energy to the electrodes for treatment of the luminal tissue.
In some embodiments, measuring the luminal dimension comprises positioning a sizing member at the treatment location within the lumen, expanding the sizing member until it engages an inside wall of the lumen, and calculating the luminal dimension at the treatment location of the esophagus based on the expansion of the sizing member. Often, expanding the sizing member comprises inflating a sizing balloon by introducing an expansion medium. The expansion medium may be a compressible or non-compressible fluid. In some embodiments, the lumen dimensions are calculated by determining the amount of the expansion medium introduced to the sizing balloon while it is inflated. For example, the mass or volume of the expansion medium can be measured by use of a mass-flow meter or the like. Optionally, a pressure sensor may be coupled to the sizing balloon, so that the luminal dimension can be calculated from the measured amount of expansion medium introduced to the balloon at a given pressure. Alternatively, the sizing member may comprise a basket, plurality of struts, or calipers, or the like. The lumen may also be measured by ultrasound, optical, or fluoroscopic imaging or by use of measuring strip.
In embodiments where a sizing balloon is employed, the sizing balloon may comprise any material or configuration. In general, the sizing balloon is cylindrical and has a known length and a diameter that is greater than the diameter of the target lumen. In this configuration, the sizing balloon is non-distensible, such as a bladder having a diameter in its fully expanded form that is larger than the lumen diameter. Suitable materials for the balloon may comprise a polymer such as polyimide or polyethylene terephthalate (PET). Alternatively, the balloon may comprise an elastomer or mixture of polymers and elastomers.
Once the lumen dimensions are determined, an electrode deployment device matching the measured luminal dimension may be selected from an inventory of devices having different electrode deployment sizes. In some embodiments, the electrode deployment device is transesophageally delivered to a treatment area within the esophagus. For example, delivering the device may be facilitated by advancing a catheter through the esophagus, wherein the catheter carries the electrode array and an expansion member. The expansion member may comprise any of the materials or configurations of the sizing member, such as an inflatable cylindrical balloon comprising a polymer such as polyimide or PET.
In some aspects of the invention, the array of electrodes or other electrode structure are arranged on a surface of a dimensionally stable support such as a non-distensible, electrode backing. The backing may comprise a thin, rectangular sheet of polymer materials such as polyimide, polyester or other flexible thermoplastic or thermosetting polymer film, polymer covered materials, or other nonconductive materials. The backing may also comprise an electrically insulating polymer, with an electro-conductive material, such as copper, deposited onto a surface. For example, an electrode pattern can be etched into the material to create an array of electrodes. The electrode pattern may be aligned in an axial or traverse direction across the backing, formed in a linear or non-linear parallel array or series of bipolar pairs, or other suitable pattern. In many embodiments, delivering energy comprises applying radiofrequency (RF) energy to tissue of the body lumen through the electrodes. Depending on the desired treatment effect, the electrodes may be arranged to control the depth and pattern of treatment. For treatment of esophageal tissue, the electrode widths are less than 3 mm, typically a width in the range from 0.1 mm to 3 mm, preferably 0.1 mm to 0.3 mm, and adjacent electrodes are spaced apart less than 3 mm, typically in the range from 0.1 mm to 3 mm, preferably from 0.1 mm to 0.3 mm. Alternatively, energy may be delivered by use of structures other than those having an array of electrodes. For example, the electrode structure may comprise a continuous electrode arranged in a helical pattern over the balloon.
In another method of the present invention, the measurement of the luminal dimension may be used to determine the amount of energy delivered to the tissue of the lumen. For example, a method for treating the tissue of a body lumen at a treatment location comprises measuring a luminal dimension at a location of the lumen, positioning an electrode deployment device at that location, deploying the expansion member to engage an electrode array to a wall of the lumen; and delivering sufficient energy to the electrode array for treatment of the luminal tissue based on the measured dimension of the lumen. In general, the amount of power delivered to the electrodes will vary depending on the type of treatment and the overall surface area of the luminal tissue to be treated. In some embodiments, the expansion member can variably expand to engage the wall of the lumen independent of the size of the lumen. For esophageal treatment, the expansion member may comprise a balloon that can expand to a range of diameters between 12 mm and 50 mm. Typically, the total energy density delivered to the esophageal tissue will be in the range from 1 J/cm2 to 50 J/cm2, usually being from 5 J/cm2 to 15 J/cm2. In order to effectively ablate the mucosal lining of the esophagus and allow re-growth of a normal mucosal lining without creating damage to underlying tissue structures, it is preferable to deliver the radiofrequency energy over a short time span in order to reduce the effects of thermal conduction of energy to deeper tissue layers, thereby creating a “searing” effect. It is preferable to deliver the radiofrequency energy within a time span of less than 5 seconds. An optimal time for effective treatment is less than 1 second, and preferably less than 0.5 second or 0.25 seconds. The lower bound on time may be limited by the ability of the RF power source to deliver high powers.
In one aspect of the invention, a method for measuring an internal dimension at a location in a body lumen comprises positioning a cylindrical balloon at a location within the lumen, inflating the balloon with an expansion medium to engage an inside wall of the lumen, monitoring the extent of engagement of the balloon, determining the amount of expansion medium in the balloon while inflated at the location, and calculating the internal dimension of the esophagus based on the length of the balloon and the measured amount of expansion medium inside the balloon. In some embodiments, the balloon is transesophageally delivered to a treatment area within the esophagus by advancing a catheter carrying the balloon through the esophagus. Often, the balloon is non-distensible and has a diameter that is greater than the diameter of the inside wall of the lumen. The balloon may be filled with an expansion medium that is a compressible fluid, such as air.
Monitoring the extent of engagement comprises determining the expansion of the balloon via a pressure sensor coupled to the balloon, wherein the extent of engagement is determined by the internal pressure exerted from the expansion medium as measured by the pressure sensor and by visual verification. The pressure sensor may comprise any device for determining the pressure inside a vessel, such as a strain gauge. Alternatively, the extent of may be monitored by determining the expansion of the balloon via visual inspection. In some embodiments, the balloon may be expanded to apply pressure to the inside wall of the lumen, thereby causing the lumen to stretch.
In one aspect of the invention, a method for determining wall compliance of an esophagus comprises positioning a balloon at a location within the esophagus, inflating the balloon with a compressible fluid, measuring the static pressure within the balloon, measuring the total amount of fluid within the balloon at at least two static pressure values, and calculating the wall compliance based on the variation in the amount of fluid between a first measured pressure and a second measured pressure. For esophageal treatment, the static pressure values to be used are typically below 10 psig, and preferably at or below 7 psig.
In another aspect, a system for treating tissue of a body lumen comprises a sizing member for measuring the cross section at a location of the lumen and a catheter having a set of individual treatment devices, each device comprising an electrode array adapted to treat a target location, wherein at least some of the arrays are adapted to treat locations having different sizes determined by the sizing member. In some embodiments, the sizing member comprises an inflatable, noncompliant sizing balloon that is oversized with respect to the inside wall of the lumen. The sizing balloon may be cylindrical with a diameter that is oversized with respect to the inside wall of the lumen. The sizing balloon may further be coupled to a pressure sensor for determining the internal pressure in the balloon from the introduction of the expansion medium. In addition, the system may further comprise a measuring means, such as a mass flow meter, for determining the amount of fluid in the sizing balloon.
In some embodiments, each of the individual treatment devices further include an expansion member comprising an inflatable balloon. Generally, each balloon is cylindrical and ranges in diameter from 12 mm to 50 mm when expanded. A balloon within the range is selected based on the measurement made from the sizing balloon so that when the balloon is expanded to its fully inflated shape, it properly engages the wall of the lumen. Typically, the expansion member is inflated with the same medium as the sizing balloon. Optionally, the treatment device may further include a pressure sensor as an extra precaution against over-distension of the organ.
In various embodiments, the present invention provides methods and systems for measuring, and treating at a controlled and uniform depth, the inner lining of a lumen within a patient. It will be appreciated that the present invention is applicable to a variety of different tissue sites and organs, including but not limited to the esophagus. A treatment apparatus including a sizing member and a treatment device comprising an expandable electrode array is provided. The sizing member is first positioned at a treatment site within the lumen. Once in place, the sizing member is expanded to engage the wall of the lumen to obtain the dimensions of the lumen. The sizing member is removed, and at least a portion of the treatment device is positioned at the tissue site, where the electrode array is expanded to contact the tissue surface according to the measurements made by the sizing member. Sufficient energy is then delivered from the electrode array to impart a desired therapeutic effect, such as cell necrosis, to a discreet layer of tissue.
Certain disorders can cause the retrograde flow of gastric or intestinal contents from the stomach 12, into the esophagus 14, as shown by arrows A and B in
In one aspect, the present invention provides methods and systems for sizing the esophagus and treating columnar epithelium of selected sites of the esophagus in order to mitigate more severe implications for the patient. In many therapeutic procedures according to the present invention, the desired treatment effect is ablation of the tissue. The term “ablation” as used herein means thermal damage to the tissue causing tissue or cell necrosis. However, some therapeutic procedures may have a desired treatment effect that falls short of ablation, e.g. some level of agitation or damage that is imparted to the tissue to inure a desired change in the cellular makeup of the tissue, rather than necrosis of the tissue. With the present invention, a variety of different energy delivery devices can be utilized to create a treatment effect in a superficial layer of tissue, while preserving intact the function of deeper layers, as described hereafter.
Cell or tissue necrosis can be achieved with the use of energy, such as radiofrequency energy, at appropriate levels to accomplish ablation of mucosal or submucosal level tissue, while substantially preserving muscularis tissue. Such ablation is designed to remove the columnar growths 20 from the portions of the esophagus 14 so affected.
As illustrated in a cross-sectional view in
In one embodiment of the invention, as illustrated in
Referring to
Ideally, the expansion medium comprises a compressible fluid, such as air. The expansion medium may alternatively comprise an incompressible fluid, such as water, saline solution, or the like. Infusion of the expansion medium into the sizing balloon may be accomplished by a positive displacement device such as a fluid-infusion pump or calibrated syringe driven by stepper motor or by hand. Alternatively, for a compressible expansion medium, pressurized air or gas may also be used. In many embodiments, the sizing device also comprises a means for determining the amount of expansion fluid transferred to the balloon, such as a calibrated syringe. A mass or volume flow meter may be coupled to the fluid delivery source for simultaneously measuring the amount of fluid in the balloon as it is inflated.
As the expansion medium is injected into balloon 42, the balloon expands radially from its axis to engage the wall of the lumen. For esophageal treatment, the walls of the esophagus 14 unfold to form a more cylindrical shape as balloon 42 expands, as illustrated in
Tests were performed to calculate the inside diameter of a member by using volume flow measurements. Various types and sizes of tubes were tested by measuring the mass of air used to inflate an oversized bladder inside the tube. As shown in
In some embodiments of the invention, a pressure sensor may be coupled to the sizing device, wherein the extent of engagement is determined by the internal pressure exerted from the expansion medium as measured by the pressure sensor or visual verification. The pressure sensor may comprise any device for determining the pressure inside a vessel, such as a strain gauge. In
In some embodiments, the measurement of the pressure inside the balloon may be used to monitor the extent of engagement of the balloon with the lumen wall. Alternatively, the extent of engagement may be monitored by determining the expansion of the balloon via visual inspection with use of an endoscope, or by ultrasound, optical, or fluoroscopic imaging (not shown).
Tests were performed on different sized rigid tubes to calculate the amount of mass required to inflate an oversized balloon in a constrained tube at various pressures. As shown in
As shown in the flow chart of
As illustrated in
When an endoscope (not shown) is used, catheter sleeve 22 can be inserted in the lumen of the endoscope, or catheter sleeve 22 can be positioned on the outside of the endoscope. Alternately, an endoscope may be used to visualize the pathway that catheter 22 should follow during placement. As well, catheter sleeve 22 can be inserted into esophagus 14 after removal of the endoscope.
An electrode support 24 is provided and can be positioned at a distal end 26 of catheter sleeve 22 to provide appropriate energy for ablation as desired. Electrode support 24 has a plurality of electrode area segments 32 attached to the surface of the support. The electrodes 32 can be configured in an array 30 of various patterns to facilitate a specific treatment by controlling the electrode size and spacing (electrode density). In various embodiments, electrode support 24 is coupled to an energy source configured for powering the array 30 at levels appropriate to provide the selectable ablation of tissue to a predetermined depth of tissue. The energy may be delivered circumferentially about the axis of the treatment device in a single step, i.e., all at one time. Alternatively, the energy may be delivered to different circumferential and/or axial sections of the esophageal wall sequentially.
In many embodiments, the support 24 may comprise a flexible, non-distensible backing. For example, the support 24 may comprise of a thin, rectangular sheet of polymer materials such as polyimide, polyester or other flexible thermoplastic or thermosetting polymer film. The support 24 may also comprise polymer covered materials, or other nonconductive materials. Additionally, the backing may include an electrically insulating polymer, with an electro-conductive material, such as copper, deposited onto a surface so that an electrode pattern can be etched into the material to create an array of electrodes.
Electrode support 24 can be operated at a controlled distance from, or in direct contact with the wall of the tissue site. This can be achieved by coupling electrode support 24 to an expandable member 28, which has a cylindrical configuration with a known, fixed length, and a diameter sized to match at its expanded state the calculated diameter of the expanded (not collapsed) lumen. Suitable expandable members include but are not limited to a balloon, non-compliant balloon, balloon with a tapered geometry, cage, frame, basket, plurality of struts, expandable member with a furled and an unfurled state, one or more springs, foam, bladder, backing material that expands to an expanded configuration when unrestrained, and the like. For esophageal treatment, it is desirable to expand the expandable member to distend the lumen sufficiently to occlude the vasculature of the submucosa, including the arterial, capillary, or venular vessels. The pressure to be exerted to do so should therefore be greater than the pressure exerted by such vessels, typically from 1 psig to 10 psig, and preferably from 4 psig to 7 psig. Generally, the expandable member for the treatment device will be selected to match the diameter measured by the sizing device at the desired pressure. Under this configuration, full expansion of the expandable member will result in the a pressure that properly distends the luminal wall. In some embodiments, it may be desirable to employ a pressure sensor or mass flow meter (not shown) as a precautionary measure so that over-distension of the lumen does not occur.
As shown in
In another embodiment, expandable member 28 is utilized to deliver the ablation energy itself. An important feature of this embodiment includes the means by which the energy is transferred from distal end 26 to expandable member 28. By way of illustration, one type of energy distribution that can be utilized is disclosed in U.S. Pat. No. 5,713,942, incorporated herein by reference, in which an expandable balloon is connected to a power source, which provides radio frequency power having the desired characteristics to selectively heat the target tissue to a desired temperature. Expandable member 28 may be constructed from electrically insulating polymer, with an electro-conductive material, such as copper, deposited onto a surface so that an electrode pattern can be etched into the material to create an array of electrodes.
Electrode support 24 can deliver a variety of different types of energy including but not limited to, radio frequency, microwave, ultrasonic, resistive heating, chemical, a heatable fluid, optical including without limitation, ultraviolet, visible, infrared, collimated or non collimated, coherent or incoherent, or other light energy, and the like. It will be appreciated that the energy, including but not limited to optical, can be used in combination with one or more sensitizing agents.
The depth of treatment obtained with treatment device 10 can be controlled by the selection of appropriate treatment parameters by the user as described in the examples set forth herein. One important parameter in controlling the depth of treatment is the electrode density of the array 30. As the spacing between electrodes decreases, the depth of treatment of the affected tissue also decreases. Very close spacing of the electrodes assures that the current and resulting ohmic heating in the tissue is limited to a very shallow depth so that injury and heating of the submucosal layer are minimized. For treatment of esophageal tissue using RF energy, it may be desirable to have a width of each RF electrode to be no more than, (i) 3 mm, (ii) 2 mm, (iii) 1 mm (iv) 0.5 mm or (v) 0.3 mm (vi) 0.1 mm and the like. Accordingly, it may be desirable to have a spacing between adjacent RF electrodes to be no more than, (i) 3 mm, (ii) 2 mm, (iii) 1 mm (iv) 0.5 mm or (v) 0.3 mm (vi) 0.1 mm and the like. The plurality of electrodes can be arranged in segments, with at least a portion of the segments being multiplexed. An RF electrode between adjacent segments can be shared by each of adjacent segments when multiplexed.
The electrode patterns of the present invention may be varied depending on the length of the site to be treated, the depth of the mucosa and submucosa, in the case of the esophagus, at the site of treatment and other factors. The electrode pattern 30 may be aligned in axial or traverse direction across the electrode support 24, or formed in a linear or non-linear parallel matrix or series of bipolar pairs or monopolar electrodes. One or more different patterns may be coupled to various locations of expandable member 28. For example, an electrode array, as illustrated in
A probe sensor may also be used with the system of the present invention to monitor and determine the depth of ablation. In one embodiment, one or more sensors (not shown), including but not limited to thermal and the like, can be included and associated with each electrode segment 32 in order to monitor the temperature from each segment and then be used for control. The control can be by way of an open or closed loop feedback system. In another embodiment, the electroconductive member can be configured to permit transmission of microwave energy to the tissue site. Treatment apparatus 10 can also include steerable and directional control devices, a probe sensor for accurately sensing depth of ablation, and the like.
Referring to
As shown in
The y connector 142 at the proximal end of the catheter sleeve includes access ports for both the thru lumen 144 and the inflation lumen 146. The thru lumen spans the entire length of the balloon catheter and exits through lumen tip 148 at the distal end of balloon 116. The inflation lumen 146 is coupled to balloon 116 so that the balloon can be inflated by delivery of a liquid, gaseous solution such as air, or the like.
In some embodiments, for delivery of apparatus 100, support 110 is tightly furled about deflated balloon 116 and placed with within a sheath (not shown). During deployment, this sheath is retracted along the shaft to expose support 110. In alternative embodiments, an elastic member (not shown) may be coupled to the support 110 to keep the support furled around balloon 116 during deployment of apparatus 100.
In order to ensure good contact between the esophageal wall and electrode array 112, slight suction may be applied to the through lumen tube to reduce the air pressure in the esophagus 14 distal to balloon 116. The application of this slight suction can be simultaneously applied to the portion of the esophagus 14 proximal to balloon 116. This suction causes the portion of the esophageal wall distended by balloon 116 to be pulled against electrode arrays 112 located on balloon 116
Apparatus 100, illustrated in
In order to effectively ablate the mucosal lining of the esophagus and allow re-growth of a normal mucosal lining without creating damage to underlying tissue structures, it is preferable to deliver the radiofrequency energy over a short time span in order to reduce the effects of thermal conduction of energy to deeper tissue layers, thereby creating a “searing” effect. It is preferable to deliver the radiofrequency energy within a time span of less than 5 seconds. An optimal time for effective treatment is less than 1 second, and preferably less than 0.5 second or 0.25 seconds. The lower bound on time may be limited by the ability of the RF power source to deliver high powers. Since the electrode area and consequently the tissue treatment area can be as much as several square centimeters, RF powers of several hundred watts would be required in order to deliver the desired energy density in short periods of time. This may pose a practical limitation on the lower limit of time. However, an RF power source configured to deliver a very short, high power, pulse of energy could be utilized. Using techniques similar to those used for flash lamp sources, or other types of capacitor discharge sources, a very high power, short pulse of RF energy can be created. This would allow treatment times of a few msec. or less. While this type of approach is feasible, in practice a more conventional RF source with a power capability of several hundred watts may be preferred.
The energy source may be manually controlled by the user and is adapted to allow the user to select the appropriate treatment time and power setting to obtain a controlled depth of ablation. The energy source can be coupled to a controller (not shown), which may be a digital or analog controller for use with the energy source, including but not limited to an RF source, or a computer with software. When the computer controller is used it can include a CPU coupled through a system bus. The system may include a keyboard, a disk drive, or other non volatile memory system, a display and other peripherals known in the art. A program memory and a data memory will also be coupled to the bus.
In some embodiments of the present invention, systems and methods are disclosed for treating luminal tissue with a single treatment device that variably expands to accommodate a number of different sized lumens. Preferably, the treatment device comprises a furled electrode support that variably engages the luminal wall while keeping the electrode density constant. Such approaches are described in detail in co-pending application Ser. No. 10/754,444, published as U.S. publication no. 2005/0171524, the full disclosure of which is incorporated herein by reference. For example, for the treatment device 100 shown in
Referring to
While the exemplary embodiments have been described in some detail, by way of example and for clarity of understanding, those of skill in the art will recognize that a variety of modification, adaptations, and changes may be employed. Hence, the scope of the present invention should be limited solely by the appending claims.
This application is a Divisional of U.S. application Ser. No. 10/754,452; filed Jan. 9, 2004, now abandoned, which is a continuation-in-part of commonly assigned, U.S. patent application Ser. No. 10/370,645, filed Feb. 19, 2003, now U.S. Pat. No. 7,530,979, which is a divisional of Ser. No. 09/714,344, filed Nov. 16, 2000, now U.S. Pat. No. 6,551,310, which claims the benefit under 35 USC 119(e) of U.S. Provisional Application No. 60/165,687 filed Nov. 16, 1999, the full disclosure of which are fully incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
552832 | Fort | Jan 1896 | A |
1798902 | Raney | Mar 1931 | A |
3517128 | Hines | Jun 1970 | A |
3901241 | Allen, Jr. | Aug 1975 | A |
3924628 | Droegemueller et al. | Dec 1975 | A |
4011872 | Komiya | Mar 1977 | A |
4196724 | Wirt et al. | Apr 1980 | A |
4275734 | Mitchiner | Jun 1981 | A |
4304239 | Perlin | Dec 1981 | A |
4311154 | Sterzer et al. | Jan 1982 | A |
4407298 | Lentz et al. | Oct 1983 | A |
4411266 | Cosman | Oct 1983 | A |
4423812 | Sato | Jan 1984 | A |
4532924 | Auth et al. | Aug 1985 | A |
4565200 | Cosman | Jan 1986 | A |
4640298 | Pless et al. | Feb 1987 | A |
4658836 | Turner | Apr 1987 | A |
4662383 | Sogawa et al. | May 1987 | A |
4674481 | Boddie, Jr. et al. | Jun 1987 | A |
4676258 | Inokuchi et al. | Jun 1987 | A |
4705041 | Kim | Nov 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4740207 | Kreamer | Apr 1988 | A |
4765331 | Petruzzi et al. | Aug 1988 | A |
4776349 | Nashef et al. | Oct 1988 | A |
4860744 | Johnson et al. | Aug 1989 | A |
4887614 | Shirakami et al. | Dec 1989 | A |
4895138 | Yabe | Jan 1990 | A |
4901737 | Toone | Feb 1990 | A |
4906203 | Margrave et al. | Mar 1990 | A |
4907589 | Cosman | Mar 1990 | A |
4930521 | Metzger et al. | Jun 1990 | A |
4943290 | Rexroth et al. | Jul 1990 | A |
4947842 | Marchosky et al. | Aug 1990 | A |
4949147 | Bacuvier | Aug 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4966597 | Cosman | Oct 1990 | A |
4969890 | Sugita et al. | Nov 1990 | A |
4976711 | Parins et al. | Dec 1990 | A |
4979948 | Geddes et al. | Dec 1990 | A |
4998539 | Delsanti | Mar 1991 | A |
5006119 | Acker et al. | Apr 1991 | A |
5010895 | Maurer et al. | Apr 1991 | A |
5019075 | Spears et al. | May 1991 | A |
5035696 | Rydell | Jul 1991 | A |
5045056 | Behl | Sep 1991 | A |
5046512 | Murchie | Sep 1991 | A |
5047028 | Qian | Sep 1991 | A |
5056532 | Hull et al. | Oct 1991 | A |
5057107 | Parins et al. | Oct 1991 | A |
5078717 | Parins et al. | Jan 1992 | A |
5083565 | Parins | Jan 1992 | A |
5084044 | Quint | Jan 1992 | A |
5088979 | Filipi et al. | Feb 1992 | A |
5094233 | Brennan | Mar 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5106360 | Ishiwara et al. | Apr 1992 | A |
5117828 | Metzger et al. | Jun 1992 | A |
5122137 | Lennox | Jun 1992 | A |
5125928 | Parins et al. | Jun 1992 | A |
5151100 | Abele et al. | Sep 1992 | A |
5156151 | Imran | Oct 1992 | A |
5163938 | Kambara et al. | Nov 1992 | A |
5171299 | Heitzmann et al. | Dec 1992 | A |
5190541 | Abele et al. | Mar 1993 | A |
5192297 | Hull | Mar 1993 | A |
5197963 | Parins | Mar 1993 | A |
5197964 | Parins | Mar 1993 | A |
5205287 | Erbel et al. | Apr 1993 | A |
5215103 | Desai | Jun 1993 | A |
5232444 | Just et al. | Aug 1993 | A |
5236413 | Feiring | Aug 1993 | A |
5242441 | Avitall | Sep 1993 | A |
5254126 | Filipi et al. | Oct 1993 | A |
5255679 | Imran | Oct 1993 | A |
5256138 | Vurek et al. | Oct 1993 | A |
5257451 | Edwards et al. | Nov 1993 | A |
5263493 | Avitall | Nov 1993 | A |
5275162 | Edwards et al. | Jan 1994 | A |
5275169 | Afromowitz et al. | Jan 1994 | A |
5275608 | Forman et al. | Jan 1994 | A |
5275610 | Eberbach | Jan 1994 | A |
5277201 | Stern | Jan 1994 | A |
5281216 | Klicek | Jan 1994 | A |
5281217 | Edwards et al. | Jan 1994 | A |
5281218 | Imran | Jan 1994 | A |
5290286 | Parins | Mar 1994 | A |
5292321 | Lee | Mar 1994 | A |
5293869 | Edwards et al. | Mar 1994 | A |
5305696 | Mendenhall | Apr 1994 | A |
5309910 | Edwards et al. | May 1994 | A |
5313943 | Houser et al. | May 1994 | A |
5314438 | Shturman | May 1994 | A |
5314466 | Stern et al. | May 1994 | A |
5316020 | Truffer | May 1994 | A |
5324284 | Imran | Jun 1994 | A |
5328467 | Edwards et al. | Jul 1994 | A |
5334196 | Scott et al. | Aug 1994 | A |
5336222 | Durgin, Jr. et al. | Aug 1994 | A |
5345936 | Pomeranz et al. | Sep 1994 | A |
5348554 | Imran et al. | Sep 1994 | A |
5363861 | Edwards et al. | Nov 1994 | A |
5365926 | Desai | Nov 1994 | A |
5365945 | Halstrom | Nov 1994 | A |
5366490 | Edwards et al. | Nov 1994 | A |
5368557 | Nita et al. | Nov 1994 | A |
5368592 | Stern et al. | Nov 1994 | A |
5370675 | Edwards et al. | Dec 1994 | A |
5370678 | Edwards et al. | Dec 1994 | A |
5383874 | Jackson et al. | Jan 1995 | A |
5383876 | Nardella | Jan 1995 | A |
5383917 | Desai et al. | Jan 1995 | A |
5385544 | Edwards et al. | Jan 1995 | A |
5397339 | Desai | Mar 1995 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5401272 | Perkins | Mar 1995 | A |
5403309 | Coleman et al. | Apr 1995 | A |
5403311 | Abele et al. | Apr 1995 | A |
5409453 | Lundquist et al. | Apr 1995 | A |
5409483 | Campbell et al. | Apr 1995 | A |
5411025 | Webster, Jr. | May 1995 | A |
5413573 | Koivukangas | May 1995 | A |
5415657 | Taymor-Luia | May 1995 | A |
5421819 | Edwards et al. | Jun 1995 | A |
5423808 | Edwards et al. | Jun 1995 | A |
5423812 | Ellman et al. | Jun 1995 | A |
5425704 | Sakurai et al. | Jun 1995 | A |
5428658 | Oettinger et al. | Jun 1995 | A |
5433739 | Sluijter et al. | Jul 1995 | A |
5435805 | Edwards | Jul 1995 | A |
5441499 | Fritzsch | Aug 1995 | A |
5443470 | Stern et al. | Aug 1995 | A |
5454782 | Perkins | Oct 1995 | A |
5454809 | Janssen | Oct 1995 | A |
5456662 | Edwards et al. | Oct 1995 | A |
5456682 | Edwards et al. | Oct 1995 | A |
5458571 | Lampropoulos et al. | Oct 1995 | A |
5458596 | Lax et al. | Oct 1995 | A |
5458597 | Edwards et al. | Oct 1995 | A |
5462545 | Wang et al. | Oct 1995 | A |
5465717 | Imran et al. | Nov 1995 | A |
5470308 | Edwards et al. | Nov 1995 | A |
5471982 | Edwards et al. | Dec 1995 | A |
5472441 | Edwards et al. | Dec 1995 | A |
5484400 | Edwards et al. | Jan 1996 | A |
5486161 | Lax et al. | Jan 1996 | A |
5490984 | Freed | Feb 1996 | A |
5496271 | Burton et al. | Mar 1996 | A |
5496311 | Abele et al. | Mar 1996 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5505728 | Ellman et al. | Apr 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5507743 | Edwards et al. | Apr 1996 | A |
5509419 | Edwards et al. | Apr 1996 | A |
5514130 | Baker | May 1996 | A |
5514131 | Edwards et al. | May 1996 | A |
5517989 | Frisbie et al. | May 1996 | A |
5520684 | Imran | May 1996 | A |
5522815 | Burgin, Jr. et al. | Jun 1996 | A |
5524622 | Wilson | Jun 1996 | A |
5531676 | Edwards et al. | Jul 1996 | A |
5531677 | Lundquist et al. | Jul 1996 | A |
5533958 | Wilk | Jul 1996 | A |
5536240 | Edwards et al. | Jul 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5540655 | Edwards et al. | Jul 1996 | A |
5542916 | Hirsch et al. | Aug 1996 | A |
5542928 | Evans et al. | Aug 1996 | A |
5549644 | Lundquist et al. | Aug 1996 | A |
5549661 | Kordis et al. | Aug 1996 | A |
RE35330 | Malone et al. | Sep 1996 | E |
5554110 | Edwards et al. | Sep 1996 | A |
5556377 | Rosen et al. | Sep 1996 | A |
5558672 | Edwards et al. | Sep 1996 | A |
5558673 | Edwards et al. | Sep 1996 | A |
5562720 | Stern et al. | Oct 1996 | A |
5566221 | Smith et al. | Oct 1996 | A |
5569241 | Edwards | Oct 1996 | A |
5571116 | Bolanos et al. | Nov 1996 | A |
5577387 | Maytal | Nov 1996 | A |
5578007 | Imran | Nov 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5588960 | Edwards et al. | Dec 1996 | A |
5591195 | Taheri et al. | Jan 1997 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5609151 | Mulier et al. | Mar 1997 | A |
5620480 | Rudie | Apr 1997 | A |
5621780 | Smith et al. | Apr 1997 | A |
5624439 | Edwards et al. | Apr 1997 | A |
5651780 | Jackson et al. | Jul 1997 | A |
5651788 | Fleischer et al. | Jul 1997 | A |
5658278 | Imran et al. | Aug 1997 | A |
5672153 | Lax et al. | Sep 1997 | A |
5676674 | Bolanos et al. | Oct 1997 | A |
5688266 | Edwards et al. | Nov 1997 | A |
5688490 | Tournier et al. | Nov 1997 | A |
5702438 | Avitall | Dec 1997 | A |
5709224 | Behl et al. | Jan 1998 | A |
5713942 | Stern et al. | Feb 1998 | A |
5716410 | Wang et al. | Feb 1998 | A |
5720293 | Quinn et al. | Feb 1998 | A |
5730128 | Pomeranz et al. | Mar 1998 | A |
5732698 | Swanson et al. | Mar 1998 | A |
5738096 | Ben-Haim | Apr 1998 | A |
5748699 | Smith | May 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5769880 | Truckai et al. | Jun 1998 | A |
5779698 | Clayman et al. | Jul 1998 | A |
5797835 | Green | Aug 1998 | A |
5797903 | Swanson et al. | Aug 1998 | A |
5800334 | Wilk | Sep 1998 | A |
5800429 | Edwards | Sep 1998 | A |
5807261 | Benaron et al. | Sep 1998 | A |
5820629 | Cox | Oct 1998 | A |
5823197 | Edwards | Oct 1998 | A |
5823955 | Kuck et al. | Oct 1998 | A |
5827273 | Edwards | Oct 1998 | A |
5830129 | Baer et al. | Nov 1998 | A |
5830213 | Panescu et al. | Nov 1998 | A |
5833688 | Sieben et al. | Nov 1998 | A |
5836874 | Swanson et al. | Nov 1998 | A |
5842984 | Avitall | Dec 1998 | A |
5846196 | Siekmeyer et al. | Dec 1998 | A |
5846235 | Pasricha et al. | Dec 1998 | A |
5860974 | Abele | Jan 1999 | A |
5861036 | Godin | Jan 1999 | A |
5863291 | Schaer | Jan 1999 | A |
5871483 | Jackson et al. | Feb 1999 | A |
5876340 | Tu et al. | Mar 1999 | A |
5888743 | Das | Mar 1999 | A |
5891134 | Goble et al. | Apr 1999 | A |
5895355 | Schaer | Apr 1999 | A |
5902263 | Patterson et al. | May 1999 | A |
5925044 | Hofmann et al. | Jul 1999 | A |
5938694 | Jaraczewski et al. | Aug 1999 | A |
5964755 | Edwards | Oct 1999 | A |
5976129 | Desai | Nov 1999 | A |
5984861 | Crowley | Nov 1999 | A |
5997534 | Tu et al. | Dec 1999 | A |
6006755 | Edwards | Dec 1999 | A |
6010511 | Murphy | Jan 2000 | A |
6012457 | Lesh | Jan 2000 | A |
6016437 | Tu et al. | Jan 2000 | A |
6023638 | Swanson et al. | Feb 2000 | A |
6027499 | Johnston et al. | Feb 2000 | A |
6033397 | Laufer et al. | Mar 2000 | A |
6039701 | Sliwa et al. | Mar 2000 | A |
6041260 | Stern et al. | Mar 2000 | A |
6044846 | Edwards | Apr 2000 | A |
6053913 | Tu et al. | Apr 2000 | A |
6056744 | Edwards | May 2000 | A |
6059719 | Yamamoto et al. | May 2000 | A |
6068629 | Haissaguerre et al. | May 2000 | A |
6071277 | Farley et al. | Jun 2000 | A |
6073052 | Zelickson et al. | Jun 2000 | A |
6086558 | Bower et al. | Jul 2000 | A |
6091993 | Bouchier et al. | Jul 2000 | A |
6091995 | Ingle et al. | Jul 2000 | A |
6092528 | Edwards | Jul 2000 | A |
6095966 | Chornenky et al. | Aug 2000 | A |
6096054 | Wyzgala et al. | Aug 2000 | A |
6102908 | Tu et al. | Aug 2000 | A |
6112123 | Kelleher et al. | Aug 2000 | A |
6120434 | Kimura et al. | Sep 2000 | A |
6123703 | Tu et al. | Sep 2000 | A |
6123718 | Tu et al. | Sep 2000 | A |
6138046 | Dalton | Oct 2000 | A |
6142994 | Swanson et al. | Nov 2000 | A |
6146149 | Daoud | Nov 2000 | A |
6162237 | Chan | Dec 2000 | A |
6179836 | Eggers et al. | Jan 2001 | B1 |
6182666 | Dobak, III | Feb 2001 | B1 |
6183468 | Swanson et al. | Feb 2001 | B1 |
6197022 | Baker | Mar 2001 | B1 |
6237355 | Li | May 2001 | B1 |
6238392 | Long | May 2001 | B1 |
6245065 | Panescu et al. | Jun 2001 | B1 |
6254598 | Edwards et al. | Jul 2001 | B1 |
6258087 | Edwards et al. | Jul 2001 | B1 |
6258118 | Baum et al. | Jul 2001 | B1 |
6270494 | Kovalcheck et al. | Aug 2001 | B1 |
6273886 | Edwards et al. | Aug 2001 | B1 |
6306129 | Little et al. | Oct 2001 | B1 |
6321121 | Zelickson et al. | Nov 2001 | B1 |
6325798 | Edwards et al. | Dec 2001 | B1 |
6325800 | Durgin et al. | Dec 2001 | B1 |
6338726 | Edwards et al. | Jan 2002 | B1 |
6355031 | Edwards et al. | Mar 2002 | B1 |
6355032 | Hovda et al. | Mar 2002 | B1 |
6358245 | Edwards et al. | Mar 2002 | B1 |
6363937 | Hovda et al. | Apr 2002 | B1 |
6383181 | Johnston et al. | May 2002 | B1 |
6394949 | Crowley et al. | May 2002 | B1 |
6402744 | Edwards et al. | Jun 2002 | B2 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6409723 | Edwards | Jun 2002 | B1 |
6415016 | Chornenky et al. | Jul 2002 | B1 |
6416511 | Lesh et al. | Jul 2002 | B1 |
6423058 | Edwards et al. | Jul 2002 | B1 |
6425877 | Edwards | Jul 2002 | B1 |
6428536 | Panescu et al. | Aug 2002 | B2 |
6432104 | Eurgin et al. | Aug 2002 | B1 |
6440128 | Edwards et al. | Aug 2002 | B1 |
6448658 | Takata et al. | Sep 2002 | B2 |
6451014 | Wakikaido et al. | Sep 2002 | B1 |
6454790 | Neuberger et al. | Sep 2002 | B1 |
6464697 | Edwards et al. | Oct 2002 | B1 |
6468272 | Koblish et al. | Oct 2002 | B1 |
6514249 | Maguire et al. | Feb 2003 | B1 |
6530234 | Dobak, III et al. | Mar 2003 | B1 |
6535768 | Baker et al. | Mar 2003 | B1 |
6544226 | Gaiser et al. | Apr 2003 | B1 |
6547776 | Gaiser et al. | Apr 2003 | B1 |
6547787 | Altman et al. | Apr 2003 | B1 |
6551302 | Rosinko et al. | Apr 2003 | B1 |
6551310 | Ganz et al. | Apr 2003 | B1 |
6551315 | Kortenbach et al. | Apr 2003 | B2 |
6562034 | Edwards et al. | May 2003 | B2 |
6572578 | Blanchard | Jun 2003 | B1 |
6572610 | Kovalcheck et al. | Jun 2003 | B2 |
6572639 | Ingle et al. | Jun 2003 | B1 |
6589238 | Edwards et al. | Jul 2003 | B2 |
6613047 | Edwards | Sep 2003 | B2 |
6641581 | Muzzammel | Nov 2003 | B2 |
6663626 | Truckai et al. | Dec 2003 | B2 |
6673070 | Edwards et al. | Jan 2004 | B2 |
6682528 | Frazier et al. | Jan 2004 | B2 |
6689130 | Arai et al. | Feb 2004 | B2 |
6695764 | Silverman et al. | Feb 2004 | B2 |
6712074 | Edwards et al. | Mar 2004 | B2 |
6712814 | Edwards et al. | Mar 2004 | B2 |
6712815 | Sampson et al. | Mar 2004 | B2 |
6740082 | Shadduck | May 2004 | B2 |
6749607 | Edwards et al. | Jun 2004 | B2 |
6752806 | Durgin et al. | Jun 2004 | B2 |
6800083 | Hiblar et al. | Oct 2004 | B2 |
6837886 | Collins et al. | Jan 2005 | B2 |
6846312 | Edwards et al. | Jan 2005 | B2 |
6860878 | Brock | Mar 2005 | B2 |
6866663 | Edwards et al. | Mar 2005 | B2 |
6872206 | Edwards et al. | Mar 2005 | B2 |
6917834 | Koblish et al. | Jul 2005 | B2 |
6918906 | Long | Jul 2005 | B2 |
6923808 | Taimisto | Aug 2005 | B2 |
6929642 | Xiao et al. | Aug 2005 | B2 |
6953469 | Ryan | Oct 2005 | B2 |
6964661 | Rioux et al. | Nov 2005 | B2 |
6971395 | Edwards et al. | Dec 2005 | B2 |
6974456 | Edwards et al. | Dec 2005 | B2 |
6994704 | Qin et al. | Feb 2006 | B2 |
7056320 | Utley et al. | Jun 2006 | B2 |
7083620 | Jahns et al. | Aug 2006 | B2 |
7089063 | Lesh et al. | Aug 2006 | B2 |
7122031 | Edwards et al. | Oct 2006 | B2 |
7125407 | Edwards et al. | Oct 2006 | B2 |
7160294 | Croft | Jan 2007 | B2 |
7165551 | Edwards | Jan 2007 | B2 |
7167758 | Baker et al. | Jan 2007 | B2 |
7179257 | West et al. | Feb 2007 | B2 |
7293563 | Utley et al. | Nov 2007 | B2 |
7326207 | Edwards | Feb 2008 | B2 |
7329254 | West et al. | Feb 2008 | B2 |
7425212 | Danek et al. | Sep 2008 | B1 |
20010041887 | Crowley | Nov 2001 | A1 |
20020128650 | McClurken | Sep 2002 | A1 |
20020156470 | Shadduck | Oct 2002 | A1 |
20020177847 | Long | Nov 2002 | A1 |
20020183739 | Long | Dec 2002 | A1 |
20030014046 | Edwards et al. | Jan 2003 | A1 |
20030093117 | Saadat | May 2003 | A1 |
20030109837 | Mcbride-Sakal | Jun 2003 | A1 |
20030153905 | Edwards et al. | Aug 2003 | A1 |
20030158550 | Ganz et al. | Aug 2003 | A1 |
20030181900 | Long | Sep 2003 | A1 |
20030181905 | Long | Sep 2003 | A1 |
20030191512 | Laufer et al. | Oct 2003 | A1 |
20030216727 | Long | Nov 2003 | A1 |
20040087936 | Stern et al. | May 2004 | A1 |
20040122452 | Deem et al. | Jun 2004 | A1 |
20040147916 | Baker | Jul 2004 | A1 |
20040153120 | Seifert et al. | Aug 2004 | A1 |
20040172016 | Bek et al. | Sep 2004 | A1 |
20040204708 | Edwards et al. | Oct 2004 | A1 |
20040215180 | Starkebaum et al. | Oct 2004 | A1 |
20040215235 | Jackson et al. | Oct 2004 | A1 |
20040215296 | Ganz et al. | Oct 2004 | A1 |
20040236316 | Danitz et al. | Nov 2004 | A1 |
20050010162 | Utley et al. | Jan 2005 | A1 |
20050033271 | Qin et al. | Feb 2005 | A1 |
20050070978 | Bek et al. | Mar 2005 | A1 |
20050090817 | Phan | Apr 2005 | A1 |
20050096713 | Starkebaum et al. | May 2005 | A1 |
20050107829 | Edwards et al. | May 2005 | A1 |
20050143727 | Koblish et al. | Jun 2005 | A1 |
20050149013 | Lee | Jul 2005 | A1 |
20050154386 | West et al. | Jul 2005 | A1 |
20050159743 | Edwards et al. | Jul 2005 | A1 |
20050171524 | Stern et al. | Aug 2005 | A1 |
20050187546 | Bek et al. | Aug 2005 | A1 |
20050215983 | Brock | Sep 2005 | A1 |
20050245926 | Edwards et al. | Nov 2005 | A1 |
20050288664 | Ford et al. | Dec 2005 | A1 |
20060009758 | Edwards et al. | Jan 2006 | A1 |
20060015162 | Edward et al. | Jan 2006 | A1 |
20060041256 | Edwards et al. | Feb 2006 | A1 |
20060069303 | Couvillon | Mar 2006 | A1 |
20060086363 | Qin et al. | Apr 2006 | A1 |
20060095032 | Jackson et al. | May 2006 | A1 |
20060259028 | Utley et al. | Nov 2006 | A1 |
20060259029 | Utley et al. | Nov 2006 | A1 |
20060259030 | Utley et al. | Nov 2006 | A1 |
20060282071 | Utley et al. | Dec 2006 | A1 |
20070066973 | Stern et al. | Mar 2007 | A1 |
20070118104 | Wallace et al. | May 2007 | A1 |
20070118106 | Utley et al. | May 2007 | A1 |
20070118159 | Deem et al. | May 2007 | A1 |
20070135809 | Utley et al. | Jun 2007 | A1 |
20070167963 | Deem et al. | Jul 2007 | A1 |
20070219570 | Deem et al. | Sep 2007 | A1 |
20080097427 | Stern et al. | Apr 2008 | A1 |
20080319350 | Wallace et al. | Dec 2008 | A1 |
20090012512 | Utley et al. | Jan 2009 | A1 |
20090012513 | Utley et al. | Jan 2009 | A1 |
20090012518 | Utley et al. | Jan 2009 | A1 |
20090177194 | Wallace et al. | Jul 2009 | A1 |
20090187181 | Shadduck | Jul 2009 | A1 |
20100063495 | Utley et al. | Mar 2010 | A1 |
20100191237 | Shadduck | Jul 2010 | A1 |
20100234840 | Jackson et al. | Sep 2010 | A1 |
Number | Date | Country |
---|---|---|
3838840 | May 1990 | DE |
4303882 | Aug 1994 | DE |
0105677 | Apr 1984 | EP |
0115420 | Aug 1984 | EP |
0139607 | May 1985 | EP |
0251745 | Jan 1988 | EP |
0521595 | Jan 1993 | EP |
0608609 | Aug 1994 | EP |
1323382 | Jul 2003 | EP |
7-184919 | Jul 1995 | JP |
8-509875 | Oct 1996 | JP |
WO 9101773 | Feb 1991 | WO |
WO 9103207 | Mar 1991 | WO |
WO 9210142 | Jun 1992 | WO |
WO 9308755 | May 1993 | WO |
WO 9407446 | Apr 1994 | WO |
WO 9410925 | May 1994 | WO |
WO 9421165 | Sep 1994 | WO |
WO 9421178 | Sep 1994 | WO |
WO 9422366 | Oct 1994 | WO |
WO 9426178 | Nov 1994 | WO |
WO 9518575 | Jul 1995 | WO |
WO 9519142 | Jul 1995 | WO |
WO 9525472 | Sep 1995 | WO |
WO 9600042 | Jan 1996 | WO |
WO 9616606 | Jun 1996 | WO |
WO 9629946 | Oct 1996 | WO |
WO 9704702 | Feb 1997 | WO |
WO 9706857 | Feb 1997 | WO |
WO 9732532 | Sep 1997 | WO |
WO 9743971 | Nov 1997 | WO |
WO 9812999 | Apr 1998 | WO |
WO 9814238 | Apr 1998 | WO |
WO 9818393 | May 1998 | WO |
WO 9903413 | Jan 1999 | WO |
WO 9935987 | Jul 1999 | WO |
WO 9942046 | Aug 1999 | WO |
WO 9955245 | Nov 1999 | WO |
WO 0001313 | Jan 2000 | WO |
WO 0059393 | Oct 2000 | WO |
WO 0062699 | Oct 2000 | WO |
WO 0066017 | Nov 2000 | WO |
WO 0066021 | Nov 2000 | WO |
WO 0066052 | Nov 2000 | WO |
WO 0069376 | Nov 2000 | WO |
WO 0122897 | Apr 2001 | WO |
WO 0135846 | May 2001 | WO |
WO 0145550 | Jun 2001 | WO |
WO 0189440 | Nov 2001 | WO |
WO 02096327 | Dec 2002 | WO |
WO 03070091 | Aug 2003 | WO |
WO 03092609 | Nov 2003 | WO |
WO 2007061984 | May 2007 | WO |
Number | Date | Country | |
---|---|---|---|
20070100333 A1 | May 2007 | US |
Number | Date | Country | |
---|---|---|---|
60165678 | Nov 1999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10754452 | Jan 2004 | US |
Child | 11633938 | US | |
Parent | 09714344 | Nov 2000 | US |
Child | 10370645 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10370645 | Feb 2003 | US |
Child | 10754452 | US |